ACTO, a Toronto, Canada-based omnichannel learning and enablement platform for life sciences, announced that it closed an $18 million Series B equity financing.
The investment was led by Questa Capital, a healthcare venture growth equity firm that actively invests in healthcare and life sciences software. Existing investors: Resolve Growth Partners, Salesforce Ventures, Panache Ventures, and MaRS Investment Accelerator Fund1 also participated in the round.
This investment by Questa Capital validates the large market opportunity to transform critical learning experiences and sales enablement approaches in the life sciences industry.
The company will use the proceeds of the investment to accelerate the growth and scale of ACTO and explore potential business and partnership opportunities.
Company: ACTO Technologies Inc.
Round: Series B
Funding Month: July 2022
Lead Investors: Questa Capital
Additional Investors: Resolve Growth Partners, Salesforce Ventures, Panache Ventures, and MaRS Investment Accelerator Fund1
Company Website: https://www.acto.com/
Software Category: Omnichannel Education platform
About the Company: ACTO’s AI-powered SaaS platform to transform their field teams’ learning journey and experience at scale. Commercial and clinical leaders leverage ACTO’s omnichannel learning platform to educate and engage learners through unified educational experiences across the care continuum. Building an ecosystem for life sciences, ACTO maintains a network of partnerships with content agencies, data providers, technology companies, and more.